

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002536 A1

(51) International Patent Classification⁷: **A61K 49/06**

Christine, M. [US/US]; 7 Tower Hill Court, St. Louis, MO 63132 (US).

(21) International Application Number:
PCT/US2003/020569

(74) Agents: **POLSTER, Philip, B., II** et al.; Pharmacia Corporation, Corporate Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).

(22) International Filing Date: 27 June 2003 (27.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/392,712 28 June 2002 (28.06.2002) US
60/392,961 1 July 2002 (01.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JONES, Claude, R.** [US/US]; 1206 Crested View Drive, St. Louis, MO 63146 (US). **BASHKIN, James, K.** [US/US]; 7739 Stanford Avenue, St. Louis, MO 63130 (US). **RADER, Randall, K.** [US/US]; 45 Oak Spring Court, St. Charles, MO 63304 (US). **KOTYK, John, J.** [US/US]; 823 Nykiel Court, Manchester, MO 63011 (US). **NEUMANN, William, L.** [US/US]; 282 W. Monroe Street, St. Louis, MO 63011 (US). **MISKO, Thomas, P.** [US/US]; 141 Heatherwood Drive, St. Louis, MO 63132 (US). **KORNMEIER,**

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND CONTRAST AGENTS USEFUL IN QUANTIFYING NITRIC OXIDE

(57) Abstract: A contrast agent for nuclear magnetic resonance spectroscopy adapted for use in a living tissue comprising at least one reporter nucleus, together with a pharmaceutically acceptable carrier is disclosed. The contrast agent exhibits a first spectral property when not bound by nitric oxide, and a second spectral property when bound by nitric oxide. Methods of using the contrast agents for the detection of nitric oxide are also disclosed.

WO 2004/002536 A1

Methods and Contrast Agents Useful in Quantifying Nitric Oxide

5 Cross Reference to Related Applications

Benefit is claimed to U.S. Provisional Application serial number 60/392,712, filed June 28, 2002, and U.S. Provisional Application serial number 60/392,961, filed July 1, 2002, the disclosures of which are incorporated herein by reference.

10 Background of the Invention

Nitrogen monoxide, also called nitric oxide or NO, is an uncharged free radical that serves as a key messenger in immune, cardiovascular, and nervous systems. The physiological activity of what was later identified as NO was initially
15 discovered in the early 1980's when it was found that vascular relaxation caused by acetylcholine is dependent on the presence of the vascular endothelium. The factor derived from the endothelium, then called endothelium-derived relaxing factor (EDRF), that mediates such vascular relaxation is now known to be NO that is generated in the vascular endothelium by one isoform of nitric oxide synthase (NOS).
20 In addition, NO is the active species derived from known nitrovasodilators including amyl nitrite, and glyceryl trinitrate. Nitric oxide is also an endogenous stimulator of soluble guanylate cyclase stimulating cGMP production. When NOS is inhibited by N-monomethylarginine (L-NMMA), cGMP formation is completely prevented. In addition to endothelium-dependent relaxation, NO is known to be involved in a
25 number of biological actions including the cytotoxicity mediated by phagocytic cells and the strengthening of cell-to-cell communication in the central nervous system.

The identification of EDRF as NO coincided with the discovery of a biochemical pathway describing the synthesis of NO from the amino acid L-arginine by the enzyme NO synthase. There are at least three types of NO synthase as follows:

- 30 (i) a constitutive, Ca^{++} /calmodulin dependent enzyme, located in the brain, that releases NO in response to receptor or physical stimulation;
- (ii) a Ca^{++} independent enzyme, a 130 kD protein, which is induced after activation of vascular smooth muscle, macrophages, endothelial cells, epithelial cells, glia and a number of other cells by endotoxin and/or cytokines; and

(iii) a constitutive, Ca^{++} /calmodulin dependent enzyme, located in the endothelium, that releases NO in response to receptor or physical stimulation.

Once expressed, inducible nitric oxide synthase (hereinafter "iNOS") generates NO continuously for long periods. Abnormally high concentrations of NO
5 can be very damaging and as a result play a crucial role in a variety of inflammatory responses and diseases such as osteoarthritis, rheumatoid arthritis, cancer, stroke, and coronary heart disease. Consequently, *in vivo* detection of nitric oxide through imaging of its distribution in human and animal tissues would provide an important biomarker for such diseases and their progression. For drug discovery and testing,
10 quantification of nitric oxide production rates and imaging tissues like articular cartilage based on the rate at which different regions of the tissue produce nitric oxide are also needed.

Because NO is highly reactive, and therefore short lived due to its tendency to combine with superoxide radicals to form peroxynitrite, or with oxygen to nitrosylate
15 tissue proteins, measurement of NO radicals has been limited by constraints in instrument sensitivity. Measuring nitric-oxide synthase (NOS) activity by monitoring the conversion of H^3 -arginine to H^3 -citrulline is currently the standard assay for NOS activity. NOS activity may be performed using a commercially available Citrulline Assay (NOS detect assay Kit; Stratagene, La Jolla, CA). Such kits typically use
20 radiolabeled arginine, and are therefore not suitable for *in vivo* use.

Various complexes of iron are known to bind nitric oxide with a resulting change in the strength of the paramagnetism that they exhibit. The dithiocarbamate complexes of iron for example exhibit this behavior and are used as spin trapping agents for detection of nitric oxide by electron spin resonance (ESR) or electron
25 paramagnetic resonance (EPR) spectroscopy and as NO activated magnetic resonance imaging (MRI) contrast agents (LJ Berliner, V Khramtsov, F Hirotada, and TL Clanton, Free Radical Biol. Med. 30(5):489-499: 2001; H Fujii, X Wan, J Zhong, LJ Berliner, Magn. Reson. Med 42:235-239; 1999).

The dithiocarbamate-iron-nitric oxide complexes described in the literature
30 work fine as spin traps for EPR measurements but their use as MRI contrast agents is less promising because of the high concentrations (approaching millimolar) needed to

produce useful contrast.

It is well known (S Fujii and T Yoshimura, Antioxidants and Redox Signaling, 2(4), 879-901 (2000)) that the iron-heme system in hemoglobin is a good spin trap for nitric oxide, one which can have high nitric oxide binding constants, long bound lifetimes, and ones which produce a useful EPR signal (SM Decatur, S Franzen, GD DePhillis, RB Dyer, WH Woodruff, and SG Boxer, Biochem., 35, 4939-4944 (1996)). This effect has been used for MRI research using the iron-heme system in blood (F DiSalle, P Barone, H Hacker, F Smaltion, and M d'Ischia, NeuroReport 8, 461-464 (1997)). As MRI contrast agents these compounds work by shortening the relaxation time of tissue water.

Finally, a study has been conducted to determine the location of NO binding in the heme pocket of whale myoglobin (Mb). This study employed mutant myoglobin, with two cysteines introduced at the proximal and distal surfaces of the Mb protein. The thiols of each cysteine were labeled with trifluoroacetyl group. ¹⁹F NMR of Trifluoroacetyl-Labeled Cysteine Mutants of Myoglobin: Structural Probes of Nitric Oxide Bound to the H93G Cavity Mutant MR Thomas and SG Boxer, Biochem. 40, 8588-8596 (2001). This mutant myoglobin would be unsuitable for *in vivo* studies, since it would be recognized by the host immune system as a foreign protein, and antibodies to the myoglobin would be expected to be raised.

20

Summary of the Invention

In a broad sense, the present invention relates to a method of quantifying nitric oxide using a contrast agent for nuclear magnetic resonance spectroscopy adapted for use in a living tissue having at least one reporter nucleus, together with a pharmaceutically acceptable carrier, where the contrast agent exhibits a first spectral property when not bound by nitric oxide, and a second spectral property when bound by nitric oxide. In one embodiment, the contrast agent exhibits paramagnetism when bound to nitric oxide, but does not exhibit paramagnetism when not bound to nitric oxide. In another embodiment, the contrast agent exhibits paramagnetism when not bound to nitric oxide, but does not exhibit paramagnetism when bound to nitric oxide.

30

In the present invention, instead of using tissue water as the source of the

nuclear magnetic resonance signal for imaging, spectroscopic signals from nuclei in the complexing agent itself are used directly as the basis for analysis.

The advantage of using compounds disclosed as spectroscopic imaging agents instead of contrast agents is that the concentrations in tissue do not have to be as high. This is particularly so with the proposed fluorinated compounds. Fluorine is a very sensitivity nucleus to use in this way and has the additional advantage of the absence of an interfering fluorine background in tissues of interest. This approach also has a lot more opportunities to use synthetic chemistry to produce a large range of new and useful molecules. In addition, a characteristic of some preferred examples is optimal T1 and T2* values of the reporter nuclei in the paramagnetic state.

In a preferred example of the invention, the signals come from fluorine nuclei that are part of the chemical structure of the complexing agent. Other NMR active isotopes, such as, for example, deuterium, protons, ^{13}C (carbon 13) and ^{31}P (phosphorus 31), and the like, could also be used alone or in combination. The resulting signals can be used as imaging biomarkers for tissues with high rate of production of nitric oxide (utilizing MRI) and/or for spectroscopic analysis of such tissues based on chemical shift and/or relaxation in magnetic resonance spectroscopy (MRS). Most preferred examples would retain the spin trapping functionality of the previously known EPR agents. That is, the paramagnetic form of the complex induced by nitric oxide will build up to a much higher concentration than the free concentration of nitric oxide itself (this results from the paramagnetic specie having a longer lifetime in tissue than nitric oxide itself (S Pou, P Tsai, S Porasuphatana, HJ Halpern, GVR Chandramouli, ED Barth, GM Rosen, Biochim. Biophys. Acta, 1427 (1999) 216-226). This gives a very large and very important boost to the sensitivity of the resulting analysis. It also has the key advantage of focusing the invention on the issue of the overall amount of nitric oxide produced in a set time period rather than the equilibrium concentration of nitric oxide.

In one embodiment of the present invention, the strength of the ligand field around the iron and the redox potential of the tissue are such that the iron is mainly in the Fe(II) oxidation state and a low spin, diamagnetic state. In this case the paramagnetism is low or non-existent. The fluorine or other reporter nuclei in the

complexing agent give magnetic resonance signals which have long relaxation times and chemical shifts which differ little or not at all from their diamagnetic values. On binding nitric oxide, a strong or much stronger paramagnetic state is formed. This can have two possible effects. First the frequency of the signals from the fluorine or other reporter nuclei can be greatly changed (typically by the hyperfine shift mechanism). If the chemical shift change is large enough, this can be detected by suitably designed MRS/MRI measurements and used to generate signals specific to regions in the biological sample where the rate of nitric oxide production is high. The second useful consequence of the formation of the paramagnetic state is that the relaxation times (T1 and/or T2 and/or T1rho) of the fluorine or other reporter nuclei can be shortened. The MRS/MRI experiments can also be designed to emphasize tissues where this has occurred. In addition, shortening relaxation times can have other consequences which an MRS/MRI experiment can detect. These include the efficiency of coherence transfer (such as, for example, from ^{19}F to ^{13}C), multiple quantum coherence formation (such as, for example, ^{19}F — ^{13}C multiple quantum coherence), and various consequences of cross correlation contributions to nuclear relaxation that are specific to paramagnetic systems (such as, for example, ^{19}F — ^{19}F dipole-dipole interaction cross correlated to a ^{19}F —paramagnetic interaction).

Another embodiment of the present invention is one in which the iron complex is paramagnetic in the absence of nitric oxide and becomes diamagnetic in its presence. This embodiment is particularly suited for use in a tissue. An example of this situation would be one in which the strength and/or the symmetry of the ligand field and the redox potential of the tissue was such that the iron was in the Fe(III) oxidation state (high or low spin) and thus paramagnetic. Reporter nuclei like fluorine show any of the consequence of paramagnetism described above. Then on binding nitric oxide the complex becomes diamagnetic and the effects described above go away. The MRS/MRI experiment can be designed and parameterized to generate images either when paramagnetism appears (above) or when it disappears due to the presence of nitric oxide in those particular regions of tissue.

Alternatively, the dinitroxide complex of Fe(III) is formed which has magnetic properties that are sufficiently unique that a MRS/MRI experiment could detect them.

It is also contemplated that other metal ions besides iron could also produce such effects.

A feature of the present invention is that the molecule or complex shows a nitric oxide dependent paramagnetism which affects the spectral properties of reporter nuclei in that molecule or complexing agent and thereby produces a nuclear magnetic resonance signal from those nuclei which is useful for nuclear magnetic imaging and/or magnetic resonance spectroscopy in one of the ways exemplified above. Thus, the invention embraces any compound which, in the presence of nitric oxide, produces the desired effects thereby enabling the analysis as well as the synthetic methods which are used to prepare specific compounds.

In another embodiment of the present invention, a method of analysis of nitric oxide quantity is provided wherein a molecule capable of binding to nitric oxide and exhibiting a nitric oxide dependent paramagnetism affecting the spectral properties of at least one reporter nucleus in said molecule is contacted with a tissue or fluid, exposing the molecule to a source of nitric oxide and then measuring the paramagnetic properties of the molecule after the molecule is exposed to the nitric oxide in the tissue or fluid. Preferred means for measuring the paramagnetic properties of the molecule bound to nitric oxide include nuclear magnetic resonance and magnetic resonance imaging.

Another embodiment of the present invention is the provision of magnetic resonance measurement methods and apparatus which may be used to implement the analysis.

Description of The Invention:

The present invention provides improved contrast agents for the detection of nitric oxide in a sample. The contrast agent should have appropriate functionality to give paramagnetism that is nitric oxide dependent. In some preferred examples the agent contains functional groups which complex iron but at the same time leave one or more iron ligand sites open for nitric oxide to bind to. In such agents, the number, nature, and symmetry of the functional groups may be selected to modulate the oxidation potential of iron and/or the spin state for a given oxidation state and/or the

binding constant of iron, and/or the transmission of hyperfine interactions to the rest of the molecule, and/or the electron relaxation time of the iron, and/or the efficiency of nitric oxide capture. Dithiocarbamates are examples of some preferred functional groups because examples of dithiocarbamates are known to hold Fe(II) mainly in its low spin diamagnetic state and to have rapid and efficient nitric oxide capture. The formation of the Fe(II)-nitric oxide pair switches this center to the paramagnetic state. Various dithiocarbamate molecules and methods of making them are known in the art, such as the compounds and methods disclosed in U.S. Patent 6,407,135 issued on June 18, 2002 to Lai et al., the disclosure of which is incorporated herein by reference.

The complexing agent should contain one or more reporter nuclei located close enough to the iron center in order to have their spectroscopic frequency or their relaxation times affected by the paramagnetic state of the iron/iron-nitric oxide-complex. In some preferred examples of the invention the reporter nuclei would be fluorine(s). Some such examples are in fact fluorinated analogs of known agents such as the MGD complexing agent.

Preferred complexing agents may also contain components or aspects that control the physical properties of the overall complex. An example is a functional group that enhances the overall water solubility of the complex.

Preferred complexing agents may also contain functional groups that affect the distribution of the complex in an animal in such a way that specific physical environments or specific tissues of special interest in an investigation are preferentially targeted. An example is the provision of an extra hydrocarbon chain to anchor the agent in membranes or other hydrophobic environments such as atherosclerotic plaque, for example.


Another example is the attachment of an inhibitor or drug candidate to the rest of the complexing agent. This portion of the agent then binds to an enzyme or receptor of particular interest and targets the nitric oxide analysis to tissues or regions with higher concentrations of such receptors. Similarly, an antibody to a target of interest may be attached to the rest of the complexing agent to target nitric oxide production in tissues expressing an epitope to such an antibody. Still another

example is a functional group (which may or may not be well removed from the reporter nuclei and the iron binding site) which simply adds net charge to the complex. For example, extra positive charge might help target the complex to regions of articular cartilage that have high levels of the negatively charged polymer aggrecan or extra negative charge to target regions of articular cartilage which are depleted in aggrecan. Still further targeting functionalities are elements of bisphosphonate drugs which are known to target bone tissue. Attaching such a targeting element could help investigate the role of NO in the bone damage that can accompany arthritis. Yet another example would be the attachment of a group increasing CNS penetrability and/or localization to Alzheimer disease plaques as in the case of putresine- and beta amyloid-modified reporter molecules.


In the case of agents working on the basis of reporter nuclei relaxation changes, there are some additional characteristics that preferred examples may have. It may be preferable to avoid shortening the T2 excessively. The excitation to produce signals for MRI takes time, often 1-2 milliseconds. To avoid loss of signal, the T2* of the reporter nuclei should be longer than this time, preferably 5-20 fold longer. On the other hand the T1 values of the reporter nuclei in the paramagnetic complex should be as short as possible subject to the limitation that T2* not be shortened to the point of resulting signal loss. The short T1 values would allow for much more signal averaging of the MRI signals in the same amount of time and therefore a great increase in sensitivity. Somewhat similar considerations apply to the corresponding MRS methods except the T2* limitations are less stringent. Synthetic chemistry can be used to construct preferred examples in one of two ways. First, this could be done by placing the reporter nuclei at positions in the complexing agent where experiment shows they should have near optimal T1 and T2* values. Second, this could be done by placing multiple reporter nuclei in the general area where, a priori, near optimal T1 and T2* values would be expected with the realization that only the one or the few with near optimal values would play a constructive role in generating MRS/MRI signals.

In the example shown below, a new compound is made by replacing the N methyl group of MGD by a trifluoromethyl group. This example has the

dithiocarbamate group known to complex Fe(II) in ways which are known to be productive for MRI contrast. It has the new feature of fluorines close to iron binding site so they have a good chance to feel the paramagnetic changes at that iron center. It has a chain with a number of hydroxyl groups that can help make the compound water-soluble. This particular example of the invention does not have a functional group rationally designed for targeting.




Such dithiocarbamates can form planar complexes with iron and bind nitric oxide as shown below:




In place of the trifluoromethyl group in the structure above, various preferred examples may have longer fluorinated carbon chains. In most cases it might be best for the chain to be long enough to introduce a lot of fluorines but short enough that all of the introduced fluorines experience a strong paramagnetic effect.


The example below has extra positive charge, which could help target the complex to regions with high negative Donnan potentials (such as, for example, articular cartilage with high aggrecan content). Alternatively, instead of NH_3^+ a negative functionality like SO_3^- could be introduced to disfavor tissues with high negative potential. To instead target hydrophobic regions like membrane surfaces or atherosclerotic plaque, the complexing agent might have a relatively long hydrocarbon chain(s) attached to the primary amine shown below.



5 Shown below is an example in which two advantageous elements are combined into the same part of the molecule (fluorine reporter nuclei incorporated into the functionality for enhanced water-solubility). There are multiple reporter nuclei (fluorines in this case) increasing distance from the paramagnetic center but in the general area where paramagnetic effects giving optimal T1 and T2* values might
 10 be expected.



Shown below is an example with a cholesterol like targeting function to
 15 target tissues with high levels of cholesterol binding proteins as well as possible hydrophobic regions like lipoproteins and atherosclerotic plaque.



The above molecules are, of course, half of a dithiocarbamate to be complexed with a metal ion.




- 5 In another embodiment of the present invention, natural or synthetic porphyrins form a part of the contrast agent, together with at least one reporter nucleus. The porphyrin may be bound to a larger molecule, or it may be bound simply to one or more reporter nuclei.

Exemplary porphyrins include heme, and synthetic porphyrins. In another
 10 embodiment of the present invention, the heme is located in a hemoglobin molecule. In yet another embodiment of the present invention, the heme is located in a myoglobin molecule. In some circumstances it might be possible to use endogenous heme. The protons around the heme ring can show very large hyperfine shifts and could thus serve as the reporter nuclei.

- 15 Methods of making synthetic porphyrins are known in the art, such as tetramerization of monopyrroles. To synthesize porphyrins containing only one type of substituent, tetramerization of monopyrroles may be used. One approach involves the reaction between a 2,5-diunsubstituted pyrrole and an aldehyde providing the bridging methine (CH) carbons (Scheme 1). This method has also been used in the

synthesis of various meso-tetraarylporphyrins, such as *meso*-tetraphenylporphyrin (Scheme 2).


Another approach of monopyrrole tetramerization involves the self-condensation of a 2-acetoxymethylpyrrole or 2-*N,N*-dimethylaminomethylpyrrole (Scheme 3). More recently, similar condensation with 2-hydroxymethylpyrroles have been carried out to synthesize various porphyrins, including porphyrins that are centrosymmetric (containing two types of substituents situated in alternate positions).




Another synthesis technique which may be advantageously employed is condensation of dipyrrolic intermediates. Developed by Fischer, the self-condensation of 1-bromo-9-methyldipyrromethenes in an organic acid melt (e.g. succinic acid) at temperatures up to 200 degrees C gives good yields of porphyrins (Scheme 4). By
5 condensing a 1,9-dibromodipyrromethene and a 1,9-dimethyldipyrromethene, this method can also be used to synthesize porphyrins in which one or both halves of the molecule are symmetrical (Scheme 5). A variation of this method involves the reaction of 1-bromo-9-bromomethyldipyrromethenes in formic acid to give porphyrins in relatively high yields (Scheme 6).

10 Although known in Fischer's time, the dipyrromethane route was not widely used because of the problem of pyrrole "redistribution" during the porphyrin formation leading to a mixture of products. However, this route became common after MacDonald, in 1960, developed milder conditions for the reaction. The MacDonald synthesis involves the self condensation of 1-unsubstituted-9-formyldipyrromethanes
15 (Scheme 7) or the condensation of a 1,9-diunsubstituted dipyrromethane and a 1,9-diformyldipyrromethane (Scheme 8) in the presence of an acid catalyst such as hydriodic acid or p-toluenesulfonic acid. This route is widely used today also because the dipyrromethanes required for the MacDonald synthesis are often more easily prepared and purified than the corresponding dipyrromethenes.


20 Another synthetic route involving a dipyrroketone and a dipyrromethane is less convenient than the two discussed above because the initial product obtained is an oxophlorin, which needs to be converted into a porphyrin (Scheme 9). The symmetry limitation and reaction condition follow those of the MacDonald synthesis with dipyrromethanes. It is also required that the dipyrroketone should contain the diformyl
25 groups since 1,9-diunsubstituted dipyrroketones are not nucleophilic enough to react with 1,9-diformyldipyrromethanes.




Scheme 4




Scheme 5




Scheme 6



Scheme 7



Scheme 8



Scheme 9

Also, porphyrins may be synthesized by cyclization of open chain tetrapyrroles, for example.

The present invention provides effective and non-invasive methods of analyzing nitric oxide quantities, and conditions mediated at least in part by
5 pathological NOS-2 (iNOS) expression without causing untoward and unacceptable adverse effects.

Suitable subjects for the administration of the formulation of the present invention include primates, man and other animals, particularly man and domesticated animals such as cats and dogs.

10 For systemic use in subjects, the compounds of the invention can be formulated as pharmaceutical or veterinary compositions. Depending on the subject to be treated, and the mode of administration, the compounds are formulated in ways consonant with these parameters. The compositions of the present invention comprise a dosage effective for imaging nitric oxide. The contrast agents of this invention are
15 preferably used in combination with a pharmaceutically acceptable carrier.

The term "pharmaceutically acceptable salt, ester, amide, and prodrug" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients
20 without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.

The term "salts" refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in
25 situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate,
30 citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like. These may include cations based

on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as, nontoxic ammonium, quaternary ammonium and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

The compositions of the present invention may be incorporated in conventional pharmaceutical formulations (*e.g.* injectable solutions) for use in imaging nitric oxide in humans or animals. Pharmaceutical compositions can be administered by subcutaneous, intravenous, or intramuscular injection, or as large volume parenteral solutions and the like. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.

For example, a parenteral composition may comprise a sterile isotonic saline solution containing between 0.1 percent and 90 percent weight to volume of the contrast agent.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, granules and gels. In such solid dosage forms, the contrast agent may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, *e.g.*, lubricating agents such as magnesium stearate. In the case of capsules,

tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert
5 diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of contrast agent that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the
10 particular mode of administration. The selection of dosage depends upon the dosage form utilized, the condition being analyzed, and the particular purpose to be achieved according to the determination of those skilled in the art.

The dosage regimen for analyzing a disease condition with the contrast agent and/or contrast agents of this invention is selected in accordance with a variety of
15 factors, including the type, age, weight, sex, diet and medical condition of the patient, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the dosage
20 regimen set forth above.

The pharmaceutical compositions of the present invention are preferably administered to a human. However, besides being useful for human nitric oxide imaging, these agents are also useful for veterinary analysis of companion animals, exotic animals and farm animals, including mammals, rodents, avians, and the like.
25 More preferred animals include horses, dogs, cats, sheep, and pigs.

In accordance with the invention the contrast agents (or mixtures thereof) are administered in a pharmaceutically acceptable carrier in sufficient concentration so as to deliver an effective amount of the active compound or compounds to the subject
30 tissue. Preferably, the pharmaceutical solutions contain one or more of the contrast agents in a concentration range of approximately 0.0001% to approximately 10%

(weight by volume) and more preferably approximately 0.0005% to approximately 1% (weight by volume).

Any method of administering drugs directly to the subject tissue, such as to a mammalian eye may be employed to administer, in accordance with the present invention to the tissue to be treated. Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (such as, for example, subTenon's), subconjunctival, intraocular, subretinal, suprachoroidal, and retrobulbar. By the term "administering directly" is meant those general systemic drug administration modes, e.g., injection directly into the patient's blood vessels, oral administration and the like, which result in the contrast agents being systemically available. More preferably, the contrast agent is injected directly into the tissue.

Various preservatives may be used in the pharmaceutical preparation. Preferred preservatives include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate, and phenylmercuric nitrate.

Likewise, various preferred vehicles may be used in topical administration, including, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose and hydroxyethyl cellulose.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride etc., mannitol and glycerin, or any other suitable or acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is pharmaceutically acceptable. Accordingly, buffers include but are not limited to, acetate buffers, titrate buffers, phosphate buffers, and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar vein pharmaceutically acceptable antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene.

One skilled in the art will appreciate that suitable methods of administering a contrast agent which is useful in the present invention are available. Although more than one route can be used to administer a particular contrast agent, a particular route can provide a more immediate and more effective reaction than another route.

Accordingly, the described routes of administration are merely exemplary and are in no way limiting.

The dose administered to an animal, particularly a human, in accordance with the present invention should be sufficient to effect the desired response in the animal over a reasonable time frame. Hence, the pharmaceutical compositions of the invention are prepared in appropriate dosage unit forms. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the strength of the particular contrast agent employed, the age, species, condition or disease state, and body weight of the animal, as well as the amount of tissue expressing nitric oxide or the amount and location of nitric oxide present. The size of the dose also will be determined by the route and timing of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular contrast agent. It will be appreciated by one of ordinary skill in the art that various conditions or disease states, in particular, chronic conditions or disease states, may require more than one quantification of nitric oxide, involving multiple administrations.

Suitable doses can be determined by conventional range-finding techniques known to those of ordinary skill in the art.

The above examples are intended to illustrate the present invention, but in no way limits the scope of the appended claims. Numerous variations will occur to those skilled in the art in light of the foregoing description.

CLAIMS

What is claimed is:

5

1. A method of analysis of nitric oxide quantity comprising:
providing a molecule capable of binding to nitric oxide and exhibiting a nitric
oxide dependent paramagnetism affecting the spectral properties of at least one
reporter nucleus in said molecule;

10 contacting said molecule with a tissue or fluid, exposing said molecule to a
source of nitric oxide; and
measuring the paramagnetic properties of said molecule after said molecule is
exposed to said nitric oxide in said tissue or fluid.

15 2. The method of claim 1 wherein said molecule contains a metal atom.

3. The method of claim 2 wherein said metal atom is iron.

4. The method of claim 3 wherein said iron is in the +2 ionization state.

20

5. The method of claim 1 wherein said method is performed in an animal.

6. The method of claim 5 wherein said animal is a mammal.

25

7. The method of claim 6 wherein said mammal is a human.




30


8. The method of claim 1 wherein said molecule is naturally occurring.

9. The method of claim 8 wherein said molecule is synthetic.
10. The method of claim 3 wherein said molecule comprises a porphyrin
5 together with at least one reporter nucleus.
11. The method of claim 10 wherein said porphyrin is a heme group.
12. The method of claim 11 wherein said heme group is located in a
10 hemoglobin molecule.
13. The method of claim 11 wherein said heme group is located in a
15 myoglobin molecule.
14. The method of claim 10 wherein said porphyrin is synthetic.
15. The method of claim 2 wherein said molecule is a dithiocarbamate,
together with at least one reporter nucleus.
- 20 16. The method of claim 15 wherein said dithiocarbamate is bound to a
functional group, said functional group providing one of: solubility, target tissue
affinity, or tissue permeability.
- 25 17. The method of claim 1 wherein said molecule is selected from the
group consisting of dithiocarbamates of the following:

01195/3/PCT

23





18. The method of claim 1 wherein said measurement of paramagnetic properties is performed by nuclear magnetic resonance.

5 19. The method of claim 1 wherein said measurement of paramagnetic properties is performed by nuclear magnetic imaging.

20. The method of claim 19 wherein said exposure to nitric oxide is in a tissue.

10 21. A contrast agent for nuclear magnetic resonance spectroscopy adapted for use in a living tissue comprising at least one reporter nucleus, together with a pharmaceutically acceptable carrier, said contrast agent exhibiting a first spectral property when not bound by nitric oxide, and a second spectral property when bound by nitric oxide.


15

22. The contrast agent of claim 21 wherein a plurality of reporter nuclei are present in said contrast agent.


23. The contrast agent of claim 21 wherein said reporter nucleus is selected from the group consisting of ¹⁹F, ¹³C, ³¹P, and deuterium.

20


24. The contrast agent of claim 21 wherein nitric oxide is complexed with a metal ion in said contrast agent.
- 5 25. The contrast agent of claim 24 wherein said metal ion is an iron atom.
26. The contrast agent of claim 25 wherein said iron atom is in the Fe^{+2} oxidation state.
- 10 27. The contrast agent of claim 24 wherein said contrast agent comprises a porphyrin molecule.
28. The contrast agent of claim of 21 wherein said living tissue is in an animal.
- 15 29. The contrast agent of claim 28 wherein said animal is a mammal.
30. The contrast agent of claim 29 wherein said mammal is a human.
- 20 31. The contrast agent of claim 21 wherein said contrast agent comprises a dithiocarbamate together with at least one reporter nucleus.
32. The contrast agent of claim 21 wherein said dithiocarbamate contains a plurality of reporter nuclei.
- 25 33. The contrast agent of claim 21 wherein said contrast agent is selected from the group consisting of dithiocarbamates of the following:




;



;



; and



34. The contrast agent of claim 21 wherein said contrast agent comprises a porphyrin together with at least one reporter nucleus.

35. The contrast agent of claim 34 wherein said porphyrin is a heme group.

5 36. The contrast agent of claim 35 wherein said heme group is located in a hemoglobin molecule.

37. The contrast agent of claim 35 wherein said heme group is located in a myoglobin molecule.

10 38. The contrast agent of claim 34 wherein said porphyrin is a synthetic porphyrin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/20569

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K49/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DI SALLE FRANCESCO ET AL: "Nitric oxide-haemoglobin interaction: A new biochemical hypothesis for signal changes in fMRI" NEUROREPORT, vol. 8, no. 2, 1997, pages 461-464, XP0009018984 & ISSN: 0959-4965 cited in the application page 461, column 2; figures -----	1-8, 10-12, 21-30, 34-36
Y		14, 38
X	US 5 741 815 A (LAI CHING-SAN) 21 April 1998 (1998-04-21) column 4, line 60 - column 6, line 64; examples 2,5,7 ----- -/--	1-7,9, 15, 20-26, 28-32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

17 October 2003

Date of mailing of the international search report

27/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Winger, R.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/20569

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERLINER LAWRENCE J ET AL: "Unique in vivo applications of spin traps" FREE RADICAL BIOLOGY AND MEDICINE, vol. 30, no. 5, 1 March 2001 (2001-03-01), pages 489-499, XP0001155626 & ISSN: 0891-5849 cited in the application	1-7, 21-26, 28-32
Y	page 492 - page 495 -----	1-38
X	WO 02 16934 A (WINYARD PAUL GRAHAM ; DAVIES CLAIRE AMANDA (GB); QUEEN MARY & WESTFIEL) 28 February 2002 (2002-02-28)	1-4,9, 15, 21-26, 28-32
Y	claims 1,13,14; example 1 -----	1-38
X	WO 94 02865 A (UNIV ILLINOIS ; US GOVERNMENT (US)) 3 February 1994 (1994-02-03) page 10, line 12 - page 11, line 26; examples 5-7 -----	1,5-7,9, 21-23, 28-30
X	DE 198 35 082 A (SCHERING AG) 3 February 2000 (2000-02-03) claims; examples 10-16 -----	21-30, 35,38
X	THOMAS MELISSA R ET AL: "19F NMR of trifluoroacetyl-labeled cysteine mutants of myoglobin: Structural probes of nitric oxide bound to the H93G cavity mutant" BIOCHEMISTRY, vol. 40, no. 29, 24 July 2001 (2001-07-24), pages 8588-8596, XP0001155628 & ISSN: 0006-2960 cited in the application abstract	21-27, 35,37
Y	US 2001/031731 A1 (BUHIMSCHI IRINA A ET AL) 18 October 2001 (2001-10-18) claim 22 -----	1-38

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/20569

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-20 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/20569

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5741815	A	21-04-1998	US 5756540 A	26-05-1998
			AU 703952 B2	01-04-1999
			AU 4930396 A	18-12-1996
			CA 2223276 A1	05-12-1996
			CN 1186495 A , B	01-07-1998
			EP 0850240 A1	01-07-1998
			JP 3393606 B2	07-04-2003
			JP 11510789 T	21-09-1999
			WO 9638457 A1	05-12-1996
			US 2003040511 A1	27-02-2003
			US 6469057 B1	22-10-2002
			US 5847004 A	08-12-1998
WO 0216934	A	28-02-2002	AU 3554502 A	04-03-2002
			CA 2420496 A1	28-02-2002
			EP 1314031 A1	28-05-2003
			WO 0216934 A1	28-02-2002
WO 9402865	A	03-02-1994	AU 4686793 A	14-02-1994
			WO 9402865 A1	03-02-1994
DE 19835082	A	03-02-2000	DE 19835082 A1	03-02-2000
			AT 247659 T	15-09-2003
			AU 5164699 A	14-02-2000
			DE 59906695 D1	25-09-2003
			WO 0005235 A1	03-02-2000
			EP 1102770 A1	30-05-2001
			JP 2002521384 T	16-07-2002
			NO 20010392 A	23-03-2001
			US 6251367 B1	26-06-2001
US 2001031731	A1	18-10-2001	AU 3285401 A	31-07-2001
			EP 1263428 A2	11-12-2002
			WO 0152835 A2	26-07-2001